Management of Secondary Hyperparathyroidism in Hemodialysis Patients by Calcitriol Injections.
|
Accession number;02A0368378
|
| Title;Management of Secondary Hyperparathyroidism in Hemodialysis Patients by Calcitriol Injections. |
| Author;
YUMITA SHIGERU
(Kojinkai Chuobyoin Jinnaibumpikenkyubu)
|
Journal Title;Prog Med
|
Journal Code:F0664B
|
ISSN:0287-3648
|
|
VOL.22;NO.3;PAGE.815-821(2002)
|
| Figure&Table&Reference;FIG.5, TBL.2, REF.25 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;To prevent development of secondary hyperparathyroidism in hemodialysis patients, serum adjusted Ca, phosphate and intact PTH levels should be controlled in 9.0-10.5mg/dL, 3.0-6.0mg/dL and 150-250pg/mL, respectively. Ca carbonate should be used as a phosphate binder. Initial dose of calcitriol injection is 1.0.MU.g/HD, and maintenance doses are between 0.5 and 1.5.MU.g/HD, referring serum adjusted Ca and intact PTH levels. In case of hypercalcemia, administration of calcitriol injections must be stopped immediately but dose of phosphate binder should not be changed. Maximum maintenance dose of calcitriol injections should be 1.5.MU.g/HD. When secondary hyperparathyroidism was not controlled by the maximum dose of calcitriol injection, percutaneous ethanol injection therapy or total parathyroidectomy should be considered. (author abst.) |
|
|
|
Related Articles;
|
|
